Michael D Jain

List of Publications by Year
in descending order

59 papers	2,402 citations	304743 22 h-index	223800 46 g-index
61 all docs	61 docs citations	61 times ranked	2468 citing authors

#	Article	IF	Citations
1	A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease. Blood Advances, 2022, 6, 259-269.	5.2	5
2	Preliminary outcomes reported from three randomized controlled trials of CD19 CAR-T cell therapies in large B cell lymphoma. Molecular Therapy, 2022, 30, 14-16.	8.2	4
3	Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell Therapy. Transplantation and Cellular Therapy, 2022, 28, 305.e1-305.e9.	1.2	14
4	Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 387-405.	4.9	124
5	Transverse myelitis after antiâ€CD19 directed CAR T cell therapy for relapsed large B cell lymphoma. EJHaem, 2022, 3, 223-227.	1.0	0
6	Imagining the cell therapist: Future CAR T cell monitoring and intervention strategies to improve patient outcomes. EJHaem, 2022, 3, 46-53.	1.0	3
7	Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma. Blood, 2022, 140, 491-503.	1.4	32
8	Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. Blood Cancer Discovery, 2022, 3, 385-393.	5.0	29
9	The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. , 2022, 10, e004475.		50
10	Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 753-759.	0.4	6
11	Tumor infiltrating lymphocytes predict survival in solid organ transplant recipients with monomorphic post-transplant lymphoproliferative disorders. Clinical Lymphoma, Myeloma and Leukemia, 2022, , .	0.4	1
12	Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL. Blood Advances, 2022, 6, 3970-3973.	5.2	6
13	Outcomes of Patients with Large B-cell Lymphoma Progressing after Axicabtagene Ciloleucel. Blood, 2021, 137, 1832-1835.	1.4	48
14	Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. Haematologica, 2021, 106, 978-986.	3.5	141
15	A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation. Blood Advances, 2021, 5, 1154-1163.	5.2	26
16	Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma. Transplantation and Cellular Therapy, 2021, 27, 242.e1-242.e6.	1.2	5
17	Quality of life in caregivers of patients receiving chimeric antigen receptor Tâ€cell therapy. Psycho-Oncology, 2021, 30, 1294-1301.	2.3	6
18	Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood, 2021, 137, 2621-2633.	1.4	137

#	Article	IF	Citations
19	CAR-HEMATOTOX: a model for CAR T-cellâ€"related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Blood, 2021, 138, 2499-2513.	1.4	160
20	Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy. International Journal of Radiation Oncology Biology Physics, 2021, 111, 1145-1154.	0.8	29
21	Seeing the light: CAR T cell targeting of lambda-restricted B cell lymphomas. Clinical Cancer Research, 2021, 27, clincanres.1450.2021.	7.0	0
22	Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell Lymphoma. Transplantation and Cellular Therapy, 2021, 27, 768.e1-768.e6.	1.2	4
23	Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial. Journal of Clinical Oncology, 2021, 39, 3034-3043.	1.6	76
24	Cytokine release syndrome and neurologic toxicities associated with chimeric antigen receptor T-cell therapy: A comprehensive review of emerging grading models. Hematology/ Oncology and Stem Cell Therapy, 2020, 13, 1-6.	0.9	12
25	Incidence and Management of Venous Thrombo-Embolism (VTE) Associated with CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy: A Single Institution Experience. Biology of Blood and Marrow Transplantation, 2020, 26, S265.	2.0	1
26	Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel. Clinical Cancer Research, 2020, 26, 4823-4831.	7.0	47
27	High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Advances, 2020, 4, 3268-3276.	5.2	134
28	Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma. Blood Advances, 2020, 4, 4086-4090.	5.2	22
29	Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. Journal of Clinical Oncology, 2020, 38, 3119-3128.	1.6	481
30	Phase II Multicenter Study of Ofatumumab in Combination with Glucocorticoids As a Primary Therapy for Chronic Graft Versus Host Disease. Biology of Blood and Marrow Transplantation, 2020, 26, S182-S183.	2.0	0
31	Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma. Blood Advances, 2020, 4, 2886-2898.	5.2	59
32	Hypofibrinogenemia in Patients Receiving CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Large B Cell Lymphoma: A Single Institution Experience. Biology of Blood and Marrow Transplantation, 2020, 26, S257-S258.	2.0	2
33	Identification of Early Predictive Markers of Toxicity and Efficacy in Patients with DLBCL Treated with Axicabtagene Ciloleucel. Biology of Blood and Marrow Transplantation, 2020, 26, S245-S246.	2.0	2
34	Incidence and Management of Effusions during CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Receptor Therapy in B-Cell Lymphoma: A Single Institution Experience. Biology of Blood and Marrow Transplantation, 2020, 26, S265-S266.	2.0	0
35	Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphomaâ€type postâ€transplant lymphoproliferative disorder. British Journal of Haematology, 2020, 189, 97-105.	2.5	12
36	A Phase II Study of Sirolimus-Based Calcineurin Inhibitor-Free Gvhd Prophylaxis after Peripheral Blood Haploidentical Transplantation with Post-Transplant Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2020, 26, S58.	2.0	3

#	Article	IF	Citations
37	Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy. British Journal of Haematology, 2019, 187, e35-e38.	2.5	35
38	Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma. International Journal of Radiation Oncology Biology Physics, 2019, 105, 1012-1021.	0.8	105
39	Obinutuzumab as bridging therapy for successful manufacturing of axicabtagene ciloleucel for transformed follicular lymphoma with circulating cells. American Journal of Hematology, 2019, 94, E245-E247.	4.1	1
40	Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T). Journal of the American College of Cardiology, 2019, 74, 3099-3108.	2.8	225
41	Management Across Settings: An Ambulatory and Community Perspective for Patients Undergoing CAR T-Cell Therapy in Multiple Care Settings. , 2019, 23, 27-34.		3
42	Concise Review: Emerging Principles from the Clinical Application of Chimeric Antigen Receptor T Cell Therapies for B Cell Malignancies. Stem Cells, 2018, 36, 36-44.	3.2	48
43	Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma. Therapeutics and Clinical Risk Management, 2018, Volume 14, 1007-1017.	2.0	45
44	Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience. Blood, 2018, 132, 91-91.	1.4	81
45	Prediction of CAR T-Related Toxicities in R/R DLBCL Patients Treated with Axicabtagene Ciloleucel Using Point of Care Cytokine Measurements. Blood, 2018, 132, 95-95.	1.4	6
46	Radiation Therapy As a Bridging Strategy for Refractory Diffuse Large B Cell Lymphoma Patients Awaiting CAR T Manufacturing of Axicabtagene Ciloleucel. Blood, 2018, 132, 4220-4220.	1.4	7
47	SubID, a non-median dichotomization tool for heterogeneous populations, reveals the pan-cancer significance of INPP4B and its regulation by EVI1 in AML. PLoS ONE, 2018, 13, e0191510.	2.5	9
48	Advances in aggressive lymphoma from the 2018 American Society of Clinical Oncology annual meeting: commentary. Clinical Advances in Hematology and Oncology, 2018, 16 Suppl 14, 20-23.	0.3	0
49	Anti-PD-1 Antibodies as a Therapeutic Strategy in Classical Hodgkin Lymphoma. Drugs, 2017, 77, 1645-1655.	10.9	5
50	CSF1R Is Associated with Poor Overall Survival in AML and Mediates Supportive Interactions Between AML and Stromal Cells in the AML Microenvironment. Blood, 2016, 128, 2666-2666.	1.4	7
51	A Single-Center Retrospective Study of 140 Patients with Post-Transplant Lymphoproliferative Disorder Following Solid Organ Transplantation. Blood, 2016, 128, 4227-4227.	1.4	0
52	INPP4B is a Biomarker of Poor Prognosis in AML Which is Associated with EVI1 Overexpression and a LSC Signature. Blood, 2016, 128, 3929-3929.	1.4	0
53	Workplace-Based Assessment of Internal Medicine Resident Diagnostic Accuracy. Journal of Graduate Medical Education, 2014, 6, 532-535.	1.3	4
54	The ASH Practice Improvement Module in Non-Hodgkin Lymphoma: Assessing the Feasibility, Reliability and Usefulness of a New Quality Improvement Tool. Blood, 2014, 124, 2651-2651.	1.4	1

#	Article	IF	Citations
55	Seek and You Shall Findâ€"But Then What Do You Do? Cold Agglutinins in Cardiopulmonary Bypass and a Single-Center Experience With Cold Agglutinin Screening Before Cardiac Surgery. Transfusion Medicine Reviews, 2013, 27, 65-73.	2.0	32
56	Cell Biology of the Endoplasmic Reticulum and the Golgi Apparatus through Proteomics. Cold Spring Harbor Perspectives in Biology, 2013, 5, a015073-a015073.	5.5	24
57	Methemoglobinemia from curing salt. Cmaj, 2013, 185, E771-E771.	2.0	2
58	Seek and You Shall Find â€“ but Then What Do You Do? Cold Agglutinins in Cardiopulmonary Bypass, and a Single Center Experience with Cold Agglutinin Screening Before Cardiac Surgery. Blood, 2012, 120, 4372-4372.	1.4	0
59	High-resolution mapping of the Gli3 mutation Extra-toesJ reveals a 51.5-kb deletion. Mammalian Genome, 2002, 13, 58-61.	2.2	80